This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.
Eligibility
Sex
ALL
Min age
6 Years
Max age
17 Years
Healthy volunteers
No
Inclusion Criteria:
Inclusion Criteria:
* Male or female participants must be 6 to 17 years of age (inclusive)
* Participants must have completed study intervention in their lead-in study
Exclusion Criteria:
* Participant has an unresolved AE or a clinically significant finding on a physical examination, vital sign assessment, or neurological assessment along with an ECG or clinical laboratory tests (if results are available by the time of enrollment) that; in the opinion of the investigator, could represent a safety concern or a condition that would be exclusionary, could prevent the participant from performing any protocol assessments, or could confound study assessments.
* Participant has known allergies or hypersensitivity to opioids
* Female participants who are currently pregnant or nursing, or plan to become pregnant or nurse during the clinical study.
* Participant has no gallbladder, (ie, agenesis of the gallbladder or cholecystectomy).
* Participant has known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction
* Participant has a history of pancreatitis; structural diseases of the pancreas, known or suspected pancreatic duct obstruction
* Participant has a history of chronic or severe constipation, or sequelae from constipation, or known or suspected mechanical GI obstruction or pseudo obstruction
* Participant has renal impairment or an unstable hepatic, metabolic, or hematologic condition.
* Participant is a current regular alcohol drinker and/or binge drinker\*, and/or has a history of alcoholism, alcohol abuse (eg, binge-drinking\*), or alcohol addiction, and/or intends to consume alcohol during the study
Primary outcome measure(s)
Percentage of Participants with Adverse Events — 52 weeks
Percentage of Participants with Clinically Significant Laboratory Values (clinical chemistry, complete blood count, urinalysis) as assessed by the Investigator — 52 weeks
Percentage of Participants with Clinically Significant ECGs as assessed by the Investigator — 52 weeks
Percentage of Participants with Clinically Significant vital sign measurements as assessed by the Investigator — 52 weeks
Percentage of Participants with any new Physical examination abnormality or worsening of change from baseline — 52 weeks
Percentage of Participants with any new neurological abnormality post baseline or worsening of change from baseline — 52 weeks
Trial sites (6)
Facility
City
Region
Status
Kindred Medical Institute, LLC /ID# 227595
Corona
California
Valencia Medical & Research Center /ID# 246221
Miami
Florida
Florida Research Center, Inc. /ID# 227597
Miami
Florida
Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 227600
Stockbridge
Georgia
IPS Research Company /ID# 227594
Oklahoma City
Oklahoma
Preferred Primary Care Physicians, Inc. /ID# 227596
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.